Hyperpolypharmacy in patients with chronic kidney disease and its impact on clinical outcomes
Abstract Hyperpolypharmacy (≥ 10 daily medications) is frequent in patients with chronic kidney disease (CKD), but its impact remains poorly characterized. This study, based on 3,011 non-dialyzed, non-transplant CKD outpatients from the CKD-REIN cohort (eGFR < 60 mL/min/1.73 m2) aimed to describe dr...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Nature Portfolio
2026-01-01
|
| Ráidu: | Scientific Reports |
| Fáttát: | |
| Liŋkkat: | https://doi.org/10.1038/s41598-025-25632-x |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|